Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology company pioneering AAV-based therapies for severe genetic disorders of the central nervous system. This page aggregates official news and press releases related to TSHA's innovative pipeline, regulatory progress, and strategic initiatives.
Investors and industry professionals will find timely updates on clinical trial developments, including TSHA-102 for Rett syndrome, regulatory designations like RMAT status, and research collaborations advancing gene therapy science. The curated collection serves as a centralized resource for tracking milestones in TSHA's mission to address unmet needs in monogenic CNS diseases.
Content spans multiple categories including therapy development updates, manufacturing advancements, partnership announcements with academic institutions, and financial disclosures. All materials maintain factual reporting on completed events without speculative commentary.
Bookmark this page for streamlined access to verified information about TSHA's progress in developing transformative genetic medicines. Check regularly for new developments in their clinical programs and scientific innovations.
Taysha Gene Therapies announced on June 3, 2024, the grant of stock options to three new employees under its 2023 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The total of 360,000 shares was offered at an exercise price of $3.62 per share, matching the closing price on the grant date. The options, with a 10-year term, will vest 25% after one year and the rest monthly over the subsequent 36 months, contingent on continued employment.
Taysha Gene Therapies reported its Q1 2024 financial results and provided a corporate update.
The company completed dosing in the first low-dose cohort of the REVEAL Phase 1/2 trial for adolescents and adults, and dosed the second pediatric patient in the same phase.
The FDA granted RMAT designation for TSHA-102, enabling expedited development.
Initial data from both trials is expected in mid-2024, with updates from higher dose cohorts due in 2H 2024.
For Q1 2024, Taysha reported an increase in R&D expenses to $20.7 million and a decrease in G&A expenses to $7.1 million, resulting in a net loss of $24.1 million.
With $124 million in cash, Taysha's resources are expected to support operations into 2026.
Taysha Gene Therapies, a gene therapy company, will release its first-quarter 2024 financial results on March 31 and host a conference call on May 14. The company focuses on AAV-based gene therapies for CNS diseases.
Taysha Gene Therapies, a clinical-stage gene therapy company, granted options to purchase 528,000 shares of common stock to four new employees under the 2023 Inducement Plan. The options have an exercise price of $2.42 per share, a 10-year term, and will vest over four years. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for TSHA-102 in Rett syndrome. This designation allows for increased dialogue with the FDA to support expedited development and review of the therapy. The RMAT designation was granted based on the safety and efficacy data from the first three patients dosed with TSHA-102 in clinical trials.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
